Los Angeles, California--(Newsfile Corp. - October 10, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: AKRO) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Akero is the subject of a report by Investors Business Daily on October 10, 2023. According to the report, the Company's "liver-disease treatment fell short in a midstage study." The report continues, "Over 36 weeks, 22% to 24% of patients who received Akero's drug had at least a one-stage improvement in fibrosis compared to 14% of the placebo group. The result wasn't statistically significant." Based on this news, shares of Akero crashed by almost 60% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/183492
